results for durvalumab in the second-line treatment of nsclc
Published 7 years ago • 368 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
5:28
durvalumab consolidation in nsclc: the pacific trial
-
3:39
results from the pacific study: durvalumab with chemoradiation for the treatment of nsclc
-
3:07
the use of durvalumab in locally advanced nsclc
-
1:18
a study of chemotherapy with durvalumab and tremelimumab in nsclc
-
1:29
updated results for pacific trial establish new standard of care in lung cancer
-
1:01
impact of durvalumab as consolidation therapy in nsclc
-
4:25
durvalumab tolerability in non–small cell lung cancer
-
1:13
phase ii study of durvalumab for patients with nsclc
-
1:38
practical considerations for durvalumab in stage 3 nsclc
-
5:13
effectively managing treatment with durvalumab
-
7:44
durvalumab (imfinzi) fda approved for stage iii nsclc: standard of care? (bmic-024)
-
1:28
durvalumab as a consolidation therapy for locally advanced nsclc
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
3:22
locally advanced nsclc: durvalumab and the pacific trial
-
1:45
enhancing benefit with durvalumab in nsclc after the pacific trial
-
6:06
stage iii nsclc: when to start durvalumab
-
4:43
treating for stage iii nsclc after progression on durvalumab
-
5:53
targeted therapy in non-small cell lung cancer
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc